Meeting
2022 ASCO Annual Meeting
MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with SN-negative melanoma.
Authors
Tina J. Hieken
Mayo Clinic, Rochester, MN
Tina J. Hieken , Michael Earl Egger , Christina Vadala Angeles , Michael C. Lowe , Erin E. Burke , Edmund Bartlett , John Robert Hyngstrom , Vernon K. Sondak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04759781
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9606)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9606
Abstract #
TPS9606
Poster Bd #
191b
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Performance of a 31-gene expression profile (GEP) test for metastatic risk prediction in cutaneous melanomas (CM) of the head and neck.
First Author: John T. Vetto
Poster
2014 ASCO Annual Meeting
Gene expression profile test (GEP) prediction of metastasis-free (MFS) and overall survival (OS) in a cohort of cutaneous melanoma (CM) patients undergoing sentinel lymph node biopsy (SLNB).
First Author: David H. Lawson
Poster
2022 ASCO Annual Meeting
Use of Merlin Assay to identify patients with a low-risk for SN metastasis in a prospective multicenter Dutch study of a primary melanoma gene-signature (CP-GEP model) to predict sentinel node status during COVID-19.
First Author: Robert Stassen
Poster
2019 ASCO Annual Meeting
Association between tumor biology and occult lymph node metastases before and after primary neoadjuvant therapy (NAT) for patients with early breast cancer.
First Author: Hans-Christian Kolberg